Mackenzie Financial
MCRB icon

Mackenzie Financial’s Seres Therapeutics MCRB Stock Holding History

Mackenzie Financial’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-3,903
Closed -$437K – 1578
2022
Q4 		$437K Buy
+3,903
New +$523K ﹤0.01% 971

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Mackenzie Financial's MCRB Position: Q1 2023 in Review

Mackenzie Financial sold out of Seres Therapeutics (MCRB) in Q1 2023, closing a stake of 3,903 shares — an estimated $437K sold.

Mackenzie Financial first reported a position in MCRB in Q4 2022 and held it in 1 quarter. The position peaked at $437K in Q4 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q1 2023.

  • Mackenzie Financial reported no remaining Seres Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Mackenzie Financial sold 3,903 Seres Therapeutics shares in Q1 2023, an estimated $437K.
  • Mackenzie Financial first reported a position in Seres Therapeutics in Q4 2022 and held it in 1 quarter.
  • Mackenzie Financial's Seres Therapeutics position peaked at $437K in Q4 2022.
  • 123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2023.

Based on Mackenzie Financial's 13F filing for Q1 2023, filed 24 Apr 2023.